Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{179253,
        author = {Snehal Kailas Bhand and Pratiksha Sambhu Kute and Aher Manjusha B.},
        title = {Formulation and Evaluation of Mouth Dissolving Tablets of Promethazine Theoclate for Enhanced Patient Compliance},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {12},
        pages = {6882-6888},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=179253},
        abstract = {The demand for Mouth Dissolving Tablets (MDTs) has significantly increased over the past decade, particularly among geriatric and pediatric populations and individuals with dysphagia (difficulty swallowing). MDTs rapidly disintegrate and dissolve in the mouth without the need for water, offering an effective solution for enhanced patient compliance. The aim of the present study was to formulate and evaluate mouth dissolving tablets of Promethazine theoclate using superdisintegrants to improve patient convenience and therapeutic efficacy. Promethazine theoclate is an antiemetic agent widely used in the management of nausea and vomiting, especially conditions associated with impaired gastric emptying and gastrointestinal disturbances. Traditional oral delivery of Promethazine theoclate is limited by extensive degradation in the acidic environment of the stomach and substantial first-pass metabolism, resulting in reduced bioavailability. This leads to challenges in achieving rapid therapeutic effects, particularly when drug loss occurs due to vomiting. The development of MDTs for Promethazine theoclate aims to bypass these obstacles by facilitating rapid disintegration and absorption through the oral mucosa, minimizing first-pass metabolism and promoting faster onset of action. The formulation was optimized using different superdisintegrants to achieve ideal tablet characteristics including hardness, disintegration time, and dissolution profile. The outcomes of this study suggest that MDTs provide a promising approach for improving patient adherence, reducing onset time, and enhancing therapeutic performance for antiemetic therapy.},
        keywords = {Promethazine theoclate, Direct compression method, Patient compliance, Evaluation parameters,},
        month = {May},
        }